Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out?
Regeneron Pharmaceuticals fell -9.8% during the past Day. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer Incyte gives you more. Incyte (INCY) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Regeneron Pharmaceuticals (REGN) stock, suggesting you may be better off investing in INCY
- INCY’s quarterly revenue growth was 20.9%, vs. REGN’s 19.0%.
- In addition, its Last 12 Months revenue growth came in at 21.5%, ahead of REGN’s 5.9%.
- INCY’s LTM margin is higher: 27.1% vs. REGN’s 25.8%.
These differences become even clearer when you look at the financials side by side. The table highlights how REGN’s fundamentals stack up against those of INCY on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| REGN | INCY | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 17.0 | 13.1 | INCY |
| Revenue Growth | |||
| Last Quarter | 19.0% | 20.9% | INCY |
| Last 12 Months | 5.9% | 21.5% | INCY |
| Last 3 Year Average | 6.4% | 15.7% | INCY |
| Operating Margins | |||
| Last 12 Months | 25.8% | 27.1% | INCY |
| Last 3 Year Average | 28.1% | 17.1% | REGN |
| Momentum | |||
| Last 3 Year Return | -15.2% | 49.6% | INCY |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
- Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy?
- OKE Looks Smarter Buy Than Pembina Pipeline Stock
- UI Looks Smarter Buy Than Cisco Systems Stock
- Better Value & Growth: AU Leads Alamos Gold Stock
- 5 Catalysts To Monitor Over In The Next 2 Quarters For AMZN Stock
- Corning Stock To $126?
See detailed fundamentals on Buy or Sell INCY Stock and Buy or Sell REGN Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| REGN Return | 31% | 14% | 22% | -19% | 9% | -9% | 46% | ||
| INCY Return | -16% | 9% | -22% | 10% | 43% | -4% | 10% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% | <=== | |
| Monthly Win Rates [3] | |||||||||
| REGN Win Rate | 67% | 50% | 58% | 50% | 50% | 20% | 49% | ||
| INCY Win Rate | 50% | 67% | 58% | 58% | 75% | 80% | 65% | <=== | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | 64% | ||
| Max Drawdowns [4] | |||||||||
| REGN Max Drawdown | -20% | -26% | -17% | -42% | -35% | -15% | -26% | ||
| INCY Max Drawdown | -37% | -20% | -39% | -23% | -27% | -18% | -27% | ||
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | -13% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 5/18/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read INCY Dip Buyer Analyses and REGN Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.
Still not sure about REGN or INCY? Consider portfolio approach.
Smart Investing Begins With Portfolios
Stocks can jump or crash, but long-term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.